---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056871"
form_type: "8-K"
ticker: "KZR"
cik: "0001645666"
company_name: "Kezar Life Sciences, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:10:22.270465+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kezar Life Sciences Q1 net loss $21.7M; cash $179.8M; clinical trials on track

## Summary
- Cash, cash equivalents and marketable securities totaled $179.8M as of March 31, 2024, down from $201.4M at Dec 31, 2023.
- Net loss $21.7M ($0.30 per share) vs $22.2M ($0.31) in Q1 2023; R&D expenses $17.2M, G&A $6.5M.
- PALIZADE Phase 2b for lupus nephritis actively enrolling; topline data expected mid-2026.
- PORTOLA Phase 2a for autoimmune hepatitis enrolling; topline data expected mid-2025.
- KZR-261 dose expansion in melanoma enrolling; initial study data expected by year-end 2024.

## SEC filing metadata
- accession: 0000950170-24-056871
- form_type: 8-K
- ticker: KZR
- cik: 0001645666
- company_name: Kezar Life Sciences, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/0000950170-24-056871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/kzr-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056871
- JSON: https://secwatch.observer/filing/0000950170-24-056871.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056871.txt

## Key facts
- Earnings Releases
  Kezar Life Sciences, Inc. reported first quarter ended March 31, 2024 results: net income $21.7 million, EPS $0.30 per basic and diluted common share.
  - Period: first quarter ended March 31, 2024
  - Net income: $21.7 million
  - EPS: $0.30 per basic and diluted common share
  - Result: reported results
  source text: Net loss for the first quarter of 2024 was $21.7 million, or $0.30 per basic and diluted common share
  evidence_url: https://www.sec.gov/Archives/edgar/data/1645666/000095017024056871/0000950170-24-056871-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.